Tiziana Life Sciences PLC(TLSA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TLSA Tiziana Life Sciences PLC

Not Yet Opened 01-14 16:00:00 EST

1.47

+0.12

+8.89%

盘后1.50

+0.03+2.04%

19:39 EST

High1.47	Low1.32	Vol354.42K
Open1.34	D1 Closing1.35	Amplitude11.11%
Mkt Cap176.40M	Tradable Cap101.11M	Total Shares120.00M
T/O501.10K	T/O Rate0.52%	Tradable Shares68.78M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"TLSA","market":"US","secType":"STK","nameCN":"Tiziana Life Sciences PLC","latestPrice":1.47,"timestamp":1768424400000,"preClose":1.35,"halted":0,"volume":354423,"hourTrading":{"tag":"盘后","latestPrice":1.5,"preClose":1.47,"latestTime":"19:39 EST","volume":3397,"amount":5051.7376,"timestamp":1768437594331},"delay":0,"floatShares":68779500,"shares":120000000,"eps":-0.1131,"marketStatus":"Not Yet Opened","change":0.12,"latestTime":"01-14 16:00:00 EST","open":1.34,"high":1.47,"low":1.32,"amount":501102.97876110004,"amplitude":0.111111,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.1131,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768467600000},"marketStatusCode":0,"adr":0,"adrRate":2,"listingDate":1542690000000,"exchange":"NASDAQ","adjPreClose":1.35,"preHourTrading":{"tag":"盘前","latestPrice":1.45,"preClose":1.35,"latestTime":"09:12 EST","volume":101,"amount":135.330001,"timestamp":1768399974862},"postHourTrading":{"tag":"盘后","latestPrice":1.5,"preClose":1.47,"latestTime":"19:39 EST","volume":3397,"amount":5051.7376,"timestamp":1768437594331},"volumeRatio":1.619799,"impliedVol":1.0079,"impliedVolPercentile":0.472},"requestUrl":"/m/hq/s/TLSA/wiki","defaultTab":"wiki","newsList":[{"id":"2602781403","title":"Tiziana Life Sciences to Present Intranasal Foralumab at Neuroscience Innovation Forum","url":"https://stock-news.laohu8.com/highlight/detail?id=2602781403","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602781403?lang=en_us&edition=fundamental","pubTime":"2026-01-09 20:00","pubTimestamp":1767960017,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences Ltd. will present at the 9th Annual Neuroscience Innovation Forum on January 11, 2026, at the Marines' Memorial Club in San Francisco. Chief Executive Officer Ivor Elrifi is scheduled to deliver a corporate presentation highlighting the company's lead candidate, intranasal foralumab, an anti-CD3 monoclonal antibody targeting neurodegenerative conditions. Senior management will also attend the event for one-on-one meetings with investors, partners, and stakeholders. The forum is part of J.P. Morgan Healthcare Conference Week and focuses on advances in therapeutics, neurotechnology, and diagnostics for neurological disorders.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tiziana Life Sciences Ltd. published the ori","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nNDL1G5GQw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0034235188.USD","NDAQ","IE00BLSP4239.USD","LU2552382132.HKD","LU1496350502.SGD","LU0943347566.SGD","TLSA","LU0320765646.SGD","IE00BBT3K403.USD","LU0942090050.USD","LU1894683348.USD","IE00BLSP4452.SGD","LU0345769631.USD","LU0265550946.USD","LU1496350171.SGD","LU2237443895.HKD","LU2023250330.USD","LU0310799852.SGD","BK4581","LU2095319765.USD","IE00B1XK9C88.USD","IE00BN8TJ469.HKD","LU0964807845.USD","LU2236285917.USD","LU1670628061.USD","LU2264538146.SGD","LU2237443382.USD","LU2746668974.SGD","BK4504","IE00BKPKM429.USD","LU2756315664.SGD","LU1162221912.USD","LU0971096721.USD","LU2756315318.SGD","IE00BWXC8680.SGD","IE00BZ1G4Q59.USD","LU2430703095.HKD","LU1116320737.USD","LU0208291251.USD","BK4585","LU2211815571.USD","LU0106831901.USD","LU0211326839.USD","LU0323591593.USD","IE0034235303.USD","LU1119994496.HKD","IE00BKDWB100.SGD","LU1551013425.SGD","LU2552382215.SGD","IE00BFXG1179.USD"],"gpt_icon":0},{"id":"2592195055","title":"Tiziana Life Sciences Executive Chairman Gabriele Cerrone Acquires 97,687 Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2592195055","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592195055?lang=en_us&edition=fundamental","pubTime":"2025-12-20 00:00","pubTimestamp":1766160058,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences Ltd. has announced that its Executive Chairman and Founder, Mr. Gabriele Cerrone, has acquired 97,687 common shares of the company. Following this transaction, Mr. Cerrone's total holding amounts to 43,374,830 common shares, representing 36.08% of the issued share capital.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tiziana Life Sciences Ltd. published the original content used to generate this news brief via GlobeNewswire  on December 19, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nNDLbmDv51:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","SG9999014013.SGD","SG9999014039.USD","IE00BGHQF748.EUR","LU2095319765.USD","SG9999014021.USD","BK4139","IE00BKPKM429.USD","LU0314104364.USD","BK4112","LU2210149790.SGD","TLSA","BK4588","LU2210150020.SGD","NDAQ","IE00B64PRP62.GBP","BK4585","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2592911723","title":"Tiziana Life Sciences Publishes AGM Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2592911723","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592911723?lang=en_us&edition=fundamental","pubTime":"2025-12-18 00:15","pubTimestamp":1765988123,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences Ltd. has published the presentation for its Annual General Meeting. The document includes proposals to be voted on at the meeting, details on proxy and poll voting results, and the outcomes for each resolution. The full presentation can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tiziana Life Sciences Ltd. published the original content used to generate this news brief on December 17, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDLKRV1z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TLSA"],"gpt_icon":0},{"id":"2592091977","title":"Tiziana Life Sciences Rings Nasdaq Closing Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2592091977","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592091977?lang=en_us&edition=fundamental","pubTime":"2025-12-17 23:34","pubTimestamp":1765985667,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences Ltd. marked a significant milestone by ringing the Closing Bell at the Nasdaq MarketSite in Times Square, New York. Executive Chairman and Founder, Gabriele Cerrone, led the ceremony, celebrating the company's recent achievements and ongoing advancements in innovative immunomodulation therapies. The event highlighted Tiziana's progress in developing its lead candidate, intranasal foralumab, and its commitment to addressing unmet medical needs in neurodegenerative and inflammatory diseases.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tiziana Life Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL4tgK5q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLSA","BK4139"],"gpt_icon":0},{"id":"2592918073","title":"Tiziana Life Sciences Doses First Patient in Phase 2 Trial of Intranasal Foralumab for Early Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2592918073","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592918073?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:45","pubTimestamp":1765979118,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences Ltd. has announced the dosing of the first patient in its Phase 2 randomized, placebo-controlled clinical trial evaluating intranasal foralumab in patients with early Alzheimer's disease. The study will assess foralumab, a fully human anti-CD3 monoclonal antibody, as both a monotherapy and in combination with FDA-approved anti-amyloid therapies, lecanemab and donanemab. The trial is based on evidence of persistent neuroinflammation in Alzheimer's patients treated with anti-amyloid therapies. Results from the trial have not yet been presented and will be generated in the future.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tiziana Life Sciences Ltd. published the original content used to generate this news brief ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL6VyPXY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","SG9999014013.SGD","BK4139","BK4112","LU2210149790.SGD","LU2095319765.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","SG9999014005.SGD","BK4588","LU0314104364.USD","SG9999014021.USD","TLSA","BK4585","NDAQ","SG9999014039.USD","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2592091874","title":"Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer’s Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2592091874","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592091874?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:45","pubTimestamp":1765979100,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUABFS1X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLSA","BK4139"],"gpt_icon":0},{"id":"2591621812","title":"Tiziana Life Sciences CEO Increases Stake With Share Purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=2591621812","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591621812?lang=en_us&edition=fundamental","pubTime":"2025-12-16 04:33","pubTimestamp":1765830800,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences (TLSA) said Monday its CEO, Ivor Elrifi, purchased 163,400 shares of common stock, bringing his total stake to 357,848 shares.Shares of the company were down over 17% in recent trading.Price: 1.47, Change: -0.31, Percent Change: -17.19","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLSA","BK4139"],"gpt_icon":0},{"id":"2591418629","title":"Tiziana Life Sciences CEO Purchases 163,400 Shares in Open Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2591418629","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591418629?lang=en_us&edition=fundamental","pubTime":"2025-12-16 04:08","pubTimestamp":1765829286,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences Ltd. announced that its Chief Executive Officer, Ivor Elrifi, has purchased 163,400 shares of Tiziana common stock in the open market. This brings his total purchased shares to 357,848.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tiziana Life Sciences Ltd. published the original content used to generate this news brief via GlobeNewswire  on December 15, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDL2cgDpP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","SG9999014039.USD","IE00B64PRP62.GBP","LU2210150020.SGD","SG9999014005.SGD","LU2210149790.SGD","LU0314104364.USD","TLSA","BK4585","IE00BGHQF748.EUR","BK4588","BK4139","BK4112","IE00BKPKM429.USD","SG9999014021.USD","LU2095319765.USD","IE00B3QW5Z07.USD","SG9999014013.SGD"],"gpt_icon":0},{"id":"2591640488","title":"Tiziana Life Sciences Falls on Withdrawn Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2591640488","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591640488?lang=en_us&edition=fundamental","pubTime":"2025-12-15 23:33","pubTimestamp":1765812780,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences shares fell after the biotechnology company said it was withdrawing a proposed public stock offering.Shares were down 13% to $1.55 in Monday morning trading. The stock has more than doubled its value year-to-date.The Boston-based company had filed a prospectus with the Securities and Exchange Commission Friday outlining preliminary steps for a public offering of shares. It said Monday morning it was withdrawing the proposal due to market conditions.The Friday filing did not specify how many shares would be offered at what value. The company said it would have used proceeds from the filing to fund the development of intranasal foralumab, its leading drug candidate.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TLSA"],"gpt_icon":0},{"id":"2591641253","title":"Tiziana Life Sciences Withdraws Proposed Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2591641253","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591641253?lang=en_us&edition=fundamental","pubTime":"2025-12-15 21:41","pubTimestamp":1765806088,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences (TLSA) said Monday it has withdrawn its proposed public offering of common shares, citing market conditions.Tiziana Life shares were 3.4% higher in premarket trading.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLSA","BK4139"],"gpt_icon":0},{"id":"2591646679","title":"BRIEF-Tiziana Life Sciences Announces Withdrawal Of Proposed Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2591646679","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591646679?lang=en_us&edition=fundamental","pubTime":"2025-12-15 20:31","pubTimestamp":1765801912,"startTime":"0","endTime":"0","summary":"BRIEF-Tiziana Life Sciences Announces Withdrawal Of Proposed Public OfferingDec 15 (Reuters) - Tiziana Life Sciences Ltd TLSA.O:TIZIANA LIFE SCIENCES ANNOUNCES WITHDRAWAL OF PROPOSED PUBLIC OFFERINGSource text: ID:nGNXDhgvgFurther company coverage: TLSA.O ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nTUA1NSCHP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLSA","BK4139"],"gpt_icon":0},{"id":"2591689646","title":"Tiziana Life Sciences: Withdrawal of Proposed Public Offering of Common Shares Due to Market Conditions","url":"https://stock-news.laohu8.com/highlight/detail?id=2591689646","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591689646?lang=en_us&edition=fundamental","pubTime":"2025-12-15 20:30","pubTimestamp":1765801807,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nFWN3XK052:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLSA","BK4139"],"gpt_icon":0},{"id":"2591686571","title":"Tiziana Life Sciences Launches Phase 2 Trial of Intranasal Foralumab for Early Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2591686571","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591686571?lang=en_us&edition=fundamental","pubTime":"2025-12-13 03:10","pubTimestamp":1765566613,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences Ltd. has announced the initiation of patient enrollment in its Phase 2 randomized, placebo-controlled clinical trial investigating intranasal foralumab, a fully human anti-CD3 monoclonal antibody, in early Alzheimer's disease. The trial will evaluate foralumab as both a monotherapy and in combination with FDA-approved anti-amyloid therapies lecanemab or donanemab. According to the company, the first patient is expected to be dosed next week. Baseline clinical assessments, cognitive testing, TSPO-PET imaging, and biomarker collection have been completed in initial participants. Results from the study have not yet been presented and will be available in the future.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tizi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDL2rX3hG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","SG9999014013.SGD","SG9999014039.USD","IE00BGHQF748.EUR","LU2095319765.USD","SG9999014021.USD","BK4139","IE00BKPKM429.USD","LU0314104364.USD","BK4112","LU2210149790.SGD","TLSA","BK4588","LU2210150020.SGD","NDAQ","IE00B64PRP62.GBP","BK4585","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2591567686","title":"Tiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer’s Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2591567686","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591567686?lang=en_us&edition=fundamental","pubTime":"2025-12-13 03:10","pubTimestamp":1765566600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nTUA1NWV6K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLSA","BK4139"],"gpt_icon":0},{"id":"2588030542","title":"Tiziana Life Sciences to Spin Out IL-6 Asset into Separate Public Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2588030542","media":"Reuters","labels":["corporation","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588030542?lang=en_us&edition=fundamental","pubTime":"2025-12-02 20:00","pubTimestamp":1764676831,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences Ltd. has announced plans to spin out its fully human anti-IL-6 receptor monoclonal antibody, TZLS-501, and related assets into a separate publicly traded company. The move aims to enhance strategic focus and unlock value for shareholders, who will receive shares in the new entity via a distribution in specie. The spinout, which will center on the IL-6 market, is subject to shareholder approval and meeting listing requirements. The decision follows increased industry interest in IL-6 pathway therapeutics, highlighted by Novartis' recent $1.4 billion acquisition of Tourmaline Bio.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tiziana Life Sciences Ltd. published the original content used to generate this news brief","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL7PC3yD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","BK4139","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4588","NDAQ","BK4112","LU2210150020.SGD","LU2210149790.SGD","TLSA","LU2095319765.USD","IE00B3QW5Z07.USD","LU0314104364.USD","BK4585"],"gpt_icon":0},{"id":"2588030878","title":"Tiziana Life Sciences Plans to Spinout Il-6 Asset Into Separate Listed Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2588030878","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588030878?lang=en_us&edition=fundamental","pubTime":"2025-12-02 20:00","pubTimestamp":1764676812,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nFWN3X80KM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TLSA"],"gpt_icon":0},{"id":"2588003089","title":"Tiziana Life Sciences Ltd - Co Shareholders to Receive Shares in New Tzls-501 Entity","url":"https://stock-news.laohu8.com/highlight/detail?id=2588003089","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588003089?lang=en_us&edition=fundamental","pubTime":"2025-12-02 20:00","pubTimestamp":1764676812,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nFWN3X80KM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLSA","BK4139"],"gpt_icon":0},{"id":"2586464475","title":"Tiziana Life Sciences Wins ALS Association Grant for Phase 2 Nasal Foralumab Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2586464475","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586464475?lang=en_us&edition=fundamental","pubTime":"2025-11-25 21:30","pubTimestamp":1764077409,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences Ltd. has received a competitive grant from the ALS Association to support its Phase 2 clinical trial of intranasal foralumab for patients with amyotrophic lateral sclerosis . The grant was awarded following a rigorous peer review process. The trial has also been accepted into the ALS MyMatch Program at the Sean M. Healey & AMG Center for ALS at Mass General Brigham and will be conducted at multiple U.S. centers within the NEALS Consortium. The funding is specifically for Tiziana Life Sciences Ltd.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tiziana Life Sciences Ltd. published the original content used to generate this news brief via GlobeNewswire  on November 25, 2025, and is solely responsible for the informa","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL32l4r3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLSA","IE00B64PRP62.GBP","LU2210150020.SGD","BK4112","LU2210149790.SGD","BK4139","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU0314104364.USD","IE00BKPKM429.USD","NDAQ","LU2095319765.USD","BK4588","BK4585"],"gpt_icon":0},{"id":"2586103475","title":"Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted Into Healey ALS Mymatch Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2586103475","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586103475?lang=en_us&edition=fundamental","pubTime":"2025-11-25 21:30","pubTimestamp":1764077400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nTUA2YJ985:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLSA","BK4139"],"gpt_icon":0},{"id":"2583750594","title":"Tiziana Life Sciences Ltd. Announces Date for Upcoming Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2583750594","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583750594?lang=en_us&edition=fundamental","pubTime":"2025-11-13 23:46","pubTimestamp":1763048785,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences Ltd. has announced that it will hold its Annual General Meeting remotely on December 16, 2025. During the meeting, shareholders will vote on several resolutions, including the re-election of John Brancaccio as a Class II director and Willy Simon as a Class III director, each to serve until the annual general meeting in 2028. Other items on the agenda include receiving the auditor's report and financial statements for the year ended December 31, 2024, and the re-appointment of PKF LittleJohn LLP as auditors, with authorization for the directors to fix the auditors' remuneration. Any other business that may properly come before the meeting or its adjournment will also be considered.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDLc3lV5h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLSA","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tizianalifesciences.com","stockEarnings":[{"period":"1week","weight":-0.02},{"period":"1month","weight":-0.0755},{"period":"3month","weight":-0.2723},{"period":"6month","weight":-0.0516},{"period":"1year","weight":1.0276},{"period":"ytd","weight":-0.0134}],"compareEarnings":[{"period":"1week","weight":0.0011},{"period":"1month","weight":0.0141},{"period":"3month","weight":0.045},{"period":"6month","weight":0.1},{"period":"1year","weight":0.1858},{"period":"ytd","weight":0.0124}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-  receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":0.05871},{"month":2,"riseRate":0.142857,"avgChangeRate":0.005731},{"month":3,"riseRate":0.428571,"avgChangeRate":0.177199},{"month":4,"riseRate":0.571429,"avgChangeRate":0.151459},{"month":5,"riseRate":0.428571,"avgChangeRate":0.199364},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.000341},{"month":7,"riseRate":0.428571,"avgChangeRate":0.326851},{"month":8,"riseRate":0.285714,"avgChangeRate":-0.143149},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.016089},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.076885},{"month":11,"riseRate":0,"avgChangeRate":-0.127748},{"month":12,"riseRate":0,"avgChangeRate":-0.132657}],"exchange":"NASDAQ","name":"Tiziana Life Sciences PLC","nameEN":"Tiziana Life Sciences PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tiziana Life Sciences PLC(TLSA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Tiziana Life Sciences PLC(TLSA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Tiziana Life Sciences PLC,TLSA,Tiziana Life Sciences PLC股票,Tiziana Life Sciences PLC股票老虎,Tiziana Life Sciences PLC股票老虎国际,Tiziana Life Sciences PLC行情,Tiziana Life Sciences PLC股票行情,Tiziana Life Sciences PLC股价,Tiziana Life Sciences PLC股市,Tiziana Life Sciences PLC股票价格,Tiziana Life Sciences PLC股票交易,Tiziana Life Sciences PLC股票购买,Tiziana Life Sciences PLC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tiziana Life Sciences PLC(TLSA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Tiziana Life Sciences PLC(TLSA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction